United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 3 minute read Pharma Industry News Pasithea Therapeutics advances cancer trial after positive safety review of PAS-004 Pasithea Therapeutics Corp. (NASDAQ: KTTA) has reached a significant milestone in its Phase 1 clinical trial of PAS-004,… byPallavi MadhirajuFebruary 5, 2025